

Peripheral Arterial Disease - Pipeline Insight, 2021

<https://marketpublishers.com/r/P59EFA9AF6EEN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: P59EFA9AF6EEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Peripheral Arterial Disease – Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Peripheral Arterial Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Peripheral Arterial Disease Understanding

Peripheral Arterial Disease: Overview

Peripheral artery disease (PAD) refers to diseases of the blood vessels located outside the heart and brain. PAD is a chronic disease in which plaque builds up in the arteries of the legs. It is more common in people who are 65 or older, but can occur at nearly any age. Smoking; high blood pressure; high cholesterol or triglycerides; diabetes; kidney failure; and obesity increase risk for PAD. While many people with peripheral artery disease have mild or no symptoms, some people have leg pain when walking. Possible symptoms include: Hair loss on the feet and legs, Numbness in the legs, A foot or the lower leg may feel cold, and leg weakness. Symptoms and medical history are being questioned by the doctor for the appropriate diagnosis of peripheral arterial disease. PAD is usually treated by aggressively managing the risk factors with lifestyle changes

and medication. This includes quitting smoking, controlling blood pressure and cholesterol, controlling diabetes, and losing weight. Surgery, medications and angioplasty are some other treatment options for peripheral arterial disease.

'Peripheral Arterial Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease treatment guidelines. The assessment part of the report embraces, in depth Peripheral Arterial Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease.

Peripheral Arterial Disease Emerging Drugs Chapters

This segment of the Peripheral Arterial Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral Arterial Disease Emerging Drugs

Rivaroxaban: Janssen Pharmaceutical

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to

activate prothrombin (factor II) to thrombin (factor IIa). A supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto; Janssen) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD) has been submitted to the Food and Drug Administration (FDA).

Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently in Phase III stage of development for the treatment of patients with Type 2 Diabetes Mellitus, and Peripheral Arterial Disease.

Further product details are provided in the report

Peripheral Arterial Disease: Therapeutic Assessment

This segment of the report provides insights about the different Peripheral Arterial Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peripheral Arterial Disease

There are approx. 20+ key companies which are developing the therapies for Peripheral Arterial Disease. The companies which have their Peripheral Arterial Disease drug candidates in the most advanced stage, i.e. Preregistration include, Janssen Pharmaceutical.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Peripheral Arterial Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral Arterial Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease drugs.

Peripheral Arterial Disease Report Insights

- Peripheral Arterial Disease Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Peripheral Arterial Disease Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Peripheral Arterial Disease drugs?

How many Peripheral Arterial Disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Arterial Disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral Arterial Disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Peripheral Arterial Disease and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Peripheral Arterial Disease: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Peripheral Arterial Disease – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Peripheral Arterial Disease companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Peripheral Arterial Disease Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Preregistration)

Comparative Analysis

Rivaroxaban: Janssen Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

JVS-100: Juventas Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early stage products (Phase I)

Comparative Analysis

FGF-1:Venturis Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Peripheral Arterial Disease Key Companies

Peripheral Arterial Disease Key Products

Peripheral Arterial Disease- Unmet Needs

Peripheral Arterial Disease- Market Drivers and Barriers

Peripheral Arterial Disease- Future Perspectives and Conclusion

Peripheral Arterial Disease Analyst Views

Peripheral Arterial Disease Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Peripheral Arterial Disease
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Peripheral Arterial Disease

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Peripheral Arterial Disease - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P59EFA9AF6EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P59EFA9AF6EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970